Computational models to predict blood-brain barrier permeation and CNS activity
- PMID: 15068364
- DOI: 10.1023/b:jcam.0000017372.32162.37
Computational models to predict blood-brain barrier permeation and CNS activity
Abstract
The blood-brain permeation of a structurally diverse set of 281 compounds was modeled using linear regression and a multivariate genetic partial least squares (G/PLS) approach. Key structural features affecting the logarithm of blood-brain partitioning (logBB) were captured through statistically significant quantitative structure-activity relationship (QSAR) models. These relationships reveal the importance of logP, polar surface area, and a variety of electrotopological indices for accurate predictions of logBB. The best models reveal an excellent correlation (r > 0.9) for a training set of 58 compounds. Likewise, the comparison of the average logBB values obtained from an ensemble of QSAR models with experimental values also verifies the statistical quality of the models (r > 0.9). The models provide good agreement (r approximately 0.7) between the predicted logBB values for 34 molecules in the external validation set and the experimental values. To further validate the models for use during the drug discovery process, a prediction set of 181 drugs with reported CNS penetration data was used. A >70% success rate is obtained by using any of the QSAR models in the qualitative prediction for CNS permeable (active) drugs. A lower success rate (approximately 60%) was obtained for the best model for CNS impermeable (inactive) drugs. Combining the predictions obtained from all the models (consensus) did not significantly improve the discrimination of CNS active and CNS inactive molecules. Finally, using the therapeutic classification as a guiding tool, the CNS penetration capability of over 2000 compounds in the Synthline database was estimated. The results were very similar to the smaller set of 181 compounds.
Similar articles
-
ADME evaluation in drug discovery. 3. Modeling blood-brain barrier partitioning using simple molecular descriptors.J Chem Inf Comput Sci. 2003 Nov-Dec;43(6):2137-52. doi: 10.1021/ci034134i. J Chem Inf Comput Sci. 2003. PMID: 14632466
-
Partial least square and hierarchical clustering in ADMET modeling: prediction of blood-brain barrier permeation of α-adrenergic and imidazoline receptor ligands.J Pharm Pharm Sci. 2013;16(4):622-47. doi: 10.18433/j3jk5p. J Pharm Pharm Sci. 2013. PMID: 24210068
-
Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System.Mol Pharm. 2016 May 2;13(5):1540-50. doi: 10.1021/acs.molpharmaceut.6b00031. Epub 2016 Apr 4. Mol Pharm. 2016. PMID: 27015243
-
Current State and Future Perspectives in QSAR Models to Predict Blood- Brain Barrier Penetration in Central Nervous System Drug R&D.Mini Rev Med Chem. 2017;17(3):247-257. doi: 10.2174/1389557516666161013110813. Mini Rev Med Chem. 2017. PMID: 27739359 Review.
-
In silico predictions of blood-brain barrier penetration: considerations to "keep in mind".J Pharmacol Exp Ther. 2005 Nov;315(2):477-83. doi: 10.1124/jpet.104.075705. Epub 2005 May 26. J Pharmacol Exp Ther. 2005. PMID: 15919767 Review.
Cited by
-
First Description of Marinoquinoline Derivatives' Activity against Toxoplasma gondii.Pharmaceutics. 2024 Feb 10;16(2):262. doi: 10.3390/pharmaceutics16020262. Pharmaceutics. 2024. PMID: 38399316 Free PMC article.
-
Computational Approach to Drug Penetration across the Blood-Brain and Blood-Milk Barrier Using Chromatographic Descriptors.Cells. 2023 Jan 27;12(3):421. doi: 10.3390/cells12030421. Cells. 2023. PMID: 36766764 Free PMC article.
-
Development of QSAR models to predict blood-brain barrier permeability.Front Pharmacol. 2022 Oct 20;13:1040838. doi: 10.3389/fphar.2022.1040838. eCollection 2022. Front Pharmacol. 2022. PMID: 36339562 Free PMC article.
-
A curated diverse molecular database of blood-brain barrier permeability with chemical descriptors.Sci Data. 2021 Oct 29;8(1):289. doi: 10.1038/s41597-021-01069-5. Sci Data. 2021. PMID: 34716354 Free PMC article.
-
Advances in Non-Animal Testing Approaches towards Accelerated Clinical Translation of Novel Nanotheranostic Therapeutics for Central Nervous System Disorders.Nanomaterials (Basel). 2021 Oct 7;11(10):2632. doi: 10.3390/nano11102632. Nanomaterials (Basel). 2021. PMID: 34685073 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources